

EXECUTIVE SUMMARY

First Half 2022




Main figures €Mn

REVENUE	EBITDA	EBIT
380.4 (+31%)	115.8 (+56%)	104.5 (+65%)
Net profit	Capex	Net cash
80.6 (+58%)	9.9 (-13%)	87.3

2022 operating revenue guidance: + 15 % - 20 %


ROVI receives the European Commission's approval of Okedi® as a treatment for schizophrenia and launches the product in Germany and UK

Operating revenue €Mn



CMO business Specialty pharmaceutical business

Specialty pharma business €Mn



Heparin franchise* €141.6 (+8%) 37% of operating revenue

LMWH €137.9 (+8%)

Bemiparin sales

€55.8m (-14%)

Spain
€34.7m

International
€21.1m

Enoxaparin sales

€82.1m (+31%)

✓ Directly marketed in Germany, UK, Italy, Portugal, Spain and Poland.

✓ Approved in 26 countries in Europe and 30 in RoW.

✓ Launched in 38 countries.


* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

CMO business €Mn


Total
€166.4m

+76%


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



EBITDA Pre-R&D¹ €Mn **€126.2m** (+47%)


R&D expenses €Mn €10.4 (-12%)

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Phase III	<ul style="list-style-type: none"> ✓ Approved in Europe ✓ In approval process in USA
Letrozole ISM® Long acting Letrozole	Breast Cancer	Phase I	Phase I started in November 2017
Risperidone, quarterly	Schizophrenia	Non-Clinical	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

Net Profit €Mn



News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

CMO

- ✓ New contracts to be announced
- ✓ Evolution of Moderna's vaccine manufacturing.

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe (already launched in Germany and UK)
- ✓ Marketing authorization for Risvan® in USA
- ✓ Discussions with FDA initiated to review Letrozole ISM® phase I results as well as next steps

1. Calculated excluding R&D expenses in H1 2022 and H1 2021